Relmada Therapeutics (RLMD) analyst forecast and price target
Analyst forecast
Consensus of 5 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Initiated Coverage | Buy | $12.00 | Jun 18, 2026 |
| Piper Sandler | Initiated Coverage | Overweight | $12.00 | Mar 24, 2026 |
| Mizuho | Maintained | Outperform | $19.00 from $10.00 | Mar 20, 2026 |
| LUCID CAPITAL MARKETS | Initiated Coverage | Buy | $14.00 | Mar 2, 2026 |
| Leerink Partners | Upgraded | Market Perform → Outperform | $8.00 | Jan 23, 2026 |
| Jefferies | Initiated Coverage | Buy | $9.00 | Dec 22, 2025 |
| Mizuho | Upgraded | Neutral → Outperform | $10.00 from $1.00 | Nov 19, 2025 |
| Mizuho | Downgraded | Outperform → Neutral | $1.00 from $23.00 | Dec 5, 2024 |
| Leerink Partners | Downgraded | Outperform → Market Perform | $1.00 from $10.00 | Dec 4, 2024 |
| Jefferies | Upgraded | Hold → Buy | $13.00 from $3.50 | Sep 17, 2024 |
| Goldman Sachs | Downgraded | Neutral → Sell | $2.00 from $3.00 | Jun 5, 2024 |
| Mizuho | Maintained | Buy | $26.00 | Jun 15, 2023 |
Frequently asked questions
Is RLMD a buy, sell, or hold?
Analysts covering Relmada Therapeutics currently average a Buy rating: 5 buy, 0 hold and 0 sell, from 5 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on RLMD?
On Jun 18, 2026, HC Wainwright & Co. initiated coverage of Relmada Therapeutics at Buy with a price target of $12.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.